格隆汇8月19日丨四环医药(00460.HK)宣布，本公司将于2025年8月29日（星期五）举行董事会会议，藉 以（其中包括）批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，并讨论及 通过（如适用）派发中期股息。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 董事會會議通知 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 八 月 二 十 九 日（星 期 五）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 中 期 業 績 及 其 發 佈， 並 討 論 及 通 過（如 適 用）派 發 中 期 股 息。 承董事會命 四環醫藥控股集團有限公司 主席兼執行董事 車馮升醫生 香 港，二 零 二 五 年 八 月 十 九 日 於 本 公 告 日 期，本 ...

Core Viewpoint - The stock price of Sihuan Pharmaceutical (00460) has decreased by 5.13% as of August 19, with a trading price of 1.48 CNY per share and a transaction volume of 96.40 million CNY [1]. Group 1: Company Overview - Sihuan Pharmaceutical Holdings Group Co., Ltd. is a leading pharmaceutical company in China's prescription drug market, primarily engaged in the production and sales of cardiovascular prescription drugs [1]. - Since 2007, the company has been the largest supplier of cardiovascular prescription drugs in the country [1]. - Key operational data includes a unique sales model, a nationwide sales network, a diversified product portfolio, and strong research and development capabilities [1]. Group 2: Financial Performance - As of the 2024 annual report, Sihuan Pharmaceutical reported total revenue of 1.901 billion CNY and a net profit of -217 million CNY [2].

消息面上，四环医药公布，集团旗下非全资附属公司惠升生物制药股份有限公司开发的司美格鲁肽注射 液上市申请获得国家药品监督管理局(NMPA)受理，用于改善成人2型糖尿病患者的血糖控制。此外，司 美格鲁肽注射液用于减重的适应症已完成III期临床入组，处于随访阶段。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇8月18日｜四环医药(0460.HK)盘中一度涨超10%，最高触及1.58港元，创2022年2月以来新高。 (责任编辑：宋政 HN002) 据悉，作为国内唯一在糖尿病及并发症领域实现全产品覆盖的生物医药企业，惠升生物的产品矩阵已形 成显著竞争力。除司美格鲁肽的几个在研管线外，公司已有近20款糖尿病及并发症药物获批上市，研发 管线的丰富性为其长期发展提供了坚实支撑。(格隆汇) ...

Core Viewpoint - Four Seasons Pharmaceutical (0460.HK) experienced a significant intraday increase of over 10%, reaching a peak of 1.58 HKD, marking the highest level since February 2022 [1] Group 1: Company Developments - The company announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd., has received acceptance for the market application of Semaglutide injection from the National Medical Products Administration (NMPA) for improving blood sugar control in adult patients with type 2 diabetes [1] - The clinical trial for Semaglutide injection's indication for weight loss has completed Phase III enrollment and is currently in the follow-up stage [1] Group 2: Competitive Position - Huisheng Biopharmaceutical is noted as the only biopharmaceutical company in China with a comprehensive product coverage in the diabetes and complications field, which enhances its competitive edge [1] - The company has nearly 20 approved diabetes and complications drugs in its product portfolio, and the richness of its research pipeline provides solid support for its long-term development [1]

智通财经获悉，四环医药(00460)涨超9%，截至发稿，涨7.69%，报1.54港元，成交额1.13亿港元。 消息面上，四环医药公布，集团旗下非全资附属公司惠升生物制药股份有限公司开发的司美格鲁肽注射 液上市申请获得国家药品监督管理局（NMPA）受理，用于改善成人2型糖尿病患者的血糖控制。此 外，司美格鲁肽注射液用于减重的适应症已完成III期临床入组，处于随访阶段。 据悉，糖尿病领域为惠升生物重点布局领域，本次司美格鲁肽注射液上市申请获国家药监局受理，是该 款药物研发进程中的又一重要进展，将有助于进一步提升集团和惠升生物在糖尿病治疗领域的核心竞争 力。 本文源自：智通财经网 ...

Core Viewpoint - The significant surge of over 200% in the stock price of Sinovant Pharmaceuticals on its debut in the Hong Kong stock market is attributed to the market's high recognition of its first domestically produced long-acting GLP-1 receptor agonist and strong confidence in the vast potential of the weight loss drug market [1] Group 1: Market Dynamics and Company Performance - The stock price of Sihuan Pharmaceutical has increased nearly 150% this year, primarily driven by the high growth of its medical aesthetics business, indicating that the value of its innovative drug segment remains significantly underestimated [1] - The long-acting GLP-1 receptor agonist semaglutide, developed by Sihuan's subsidiary Huisheng Biopharma, has recently had its application for market approval accepted, with its Phase III clinical trial for weight loss now completed and in the follow-up stage, indicating imminent commercialization [3][4] Group 2: Product Advantages and Market Potential - Semaglutide's core advantages lie in its unique mechanism of action and clinical value, enhancing insulin secretion and suppressing glucagon secretion in a glucose-dependent manner, which has been recognized by global health authorities [5] - The drug's potential extends beyond glycemic control, as it can also reduce appetite and caloric intake, making it applicable in the treatment of metabolic diseases [5][6] Group 3: Industry Challenges and Opportunities - The global prevalence of diabetes and obesity presents significant challenges to public health, with the International Diabetes Federation projecting that the number of adults with diabetes will reach 589 million by 2024, and 853 million by 2050 [7][9] - Traditional therapies have limitations in managing these conditions, positioning GLP-1 therapies as a breakthrough direction in diabetes treatment and a key solution to metabolic disease challenges [9] Group 4: Competitive Positioning and Future Outlook - Huisheng Biopharma has established itself in the first tier of the industry, leveraging its first-mover advantage with semaglutide and other innovative products [11] - The company has built a comprehensive platform for diabetes treatment, with nearly 20 approved drugs and a robust pipeline, enhancing its competitive edge in the market [13] - Huisheng's integrated model of R&D, production, and sales ensures rapid market response and product quality, while its global partnerships are paving the way for international market expansion [15][16]

Group 1 - The core point of the article is that Sihuan Pharmaceutical (00460) has seen its stock price increase by over 9%, currently trading at 1.54 HKD with a transaction volume of 113 million HKD, following the acceptance of a listing application for semaglutide injection by the National Medical Products Administration (NMPA) [1] - The semaglutide injection is intended for improving blood sugar control in adult patients with type 2 diabetes, marking a significant advancement in the drug development process for Sihuan Pharmaceutical [1] - The drug has also completed Phase III clinical enrollment for its weight loss indication and is currently in the follow-up stage, indicating ongoing progress in its clinical development [1] Group 2 - Diabetes treatment is a key focus area for Huisheng Biopharmaceutical, a non-wholly owned subsidiary of Sihuan Pharmaceutical, and the acceptance of the listing application enhances the company's competitive edge in this therapeutic area [1]

四环医药(00460)涨超9%，截至发稿，涨7.69%，报1.54港元，成交额1.13亿港元。 消息面上，四环医药公布，集团旗下非全资附属公司惠升生物制药股份有限公司开发的司美格鲁肽注射 液上市申请获得国家药品监督管理局(NMPA)受理，用于改善成人2型糖尿病患者的血糖控制。此外，司 美格鲁肽注射液用于减重的适应症已完成III期临床入组，处于随访阶段。 据悉，糖尿病领域为惠升生物重点布局领域，本次司美格鲁肽注射液上市申请获国家药监局受理，是该 款药物研发进程中的又一重要进展，将有助于进一步提升集团和惠升生物在糖尿病治疗领域的核心竞争 力。 ...

Core Viewpoint - The significant surge of over 200% in the stock price of Sinovant Pharmaceuticals on its debut in the Hong Kong stock market is attributed to the market's high recognition of its first domestically produced long-acting GLP-1 receptor agonist and strong confidence in the vast potential of the weight loss drug market [1] Investment Opportunities - The rise of innovative drug sectors presents potential investment opportunities, as exemplified by the stock performance of Four Seasons Pharmaceuticals, which has increased nearly 150% this year, primarily due to the high growth of its medical aesthetics business [2] - The value of Four Seasons' innovative drug segment remains significantly underestimated, indicating further growth potential [2][5] Product Development - Four Seasons Pharmaceuticals' subsidiary, Huisheng Biopharma, has received acceptance for the market application of its long-acting GLP-1 receptor agonist, Semaglutide, for improving blood sugar control in type 2 diabetes patients, with its weight loss indication entering the follow-up phase of clinical trials [4] - Semaglutide's unique mechanism and clinical value position it as a key player in managing both blood sugar and weight, aligning with global treatment guidelines [6][10] Market Dynamics - The global diabetes and obesity epidemic presents a significant challenge, with the International Diabetes Federation projecting that the number of adults with diabetes will reach 589 million by 2024, with China having the highest number of patients [8] - Traditional treatment options are limited, making GLP-1 therapies a breakthrough direction for diabetes treatment and a key solution for metabolic diseases [10] Competitive Landscape - Huisheng Biopharma has established itself as a leading player in the diabetes treatment sector, with a comprehensive product matrix that includes nearly 20 approved drugs for diabetes and its complications [14] - The company operates a full industry chain model that enhances its ability to respond to market demands and ensures product quality and supply chain stability [16] Global Expansion - Huisheng Biopharma has made significant strides in global expansion, with partnerships in various countries to promote its diabetes medications, and has completed FDA registration for Semaglutide [16] Conclusion - The innovative drug segment of Four Seasons Pharmaceuticals is poised for continued growth, supported by a robust cash reserve of nearly 4 billion and the commercialization of key products like Semaglutide [17]